A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Trastuzumab for Patients With HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer.

Trial Profile

A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Trastuzumab for Patients With HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Ridaforolimus (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors ARIAD Pharmaceuticals; Merck & Co
  • Most Recent Events

    • 24 Jul 2012 Planned number of patients changed from 37 to 66 as reported by European Clinical Trials Database record.
    • 23 Jun 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 23 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top